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Beneficial Effects of Valsartan in Asymptomatic
Individuals With Vascular or Cardiac Abnormalities
The DETECTIV Pilot Study
Daniel A. Duprez, MD, PHD, FACC, Natalia D. Florea, MD, Kathryn Jones, Jay N. Cohn, MD, FACC
Minneapolis, Minnesota
Objectives We studied the efficacy of valsartan (Val) to slow cardiovascular disease progression in asymptomatic high-risk
prehypertensive or hypertensive patients with blood pressure (BP) controlled to 140/90 mm Hg and with evi-
dence for functional or structural alterations in the cardiovascular system.
Background Identifying individuals with early markers for cardiovascular disease raises the possibility for pharmacotherapy
to slow progression and delay or prevent future morbid events.
Methods Seventy-six subjects with a Rasmussen Disease Score (RDS) of 6 or higher were randomized double-blind to re-
ceive placebo (Plac) or Val 160 mg once daily for 6 months followed by 6 months of single-blind Val in both
groups. A panel of 10 tests, including large and small artery elasticity, resting and treadmill exercise BP, carotid
intimal-media thickness, retinal vascular photography, micro-albuminuria, electrocardiography, echocardiogra-
phy, and plasma B-type natriuretic peptide, was performed at baseline and after 6 and 12 months of treatment.
Each test result was scored as normal (0), borderline (1), or abnormal (2), and the total RDS was calculated by
adding all the scores of the individual tests.
Results Valsartan significantly reduced the RDS after 6 months versus Plac (p  0.03) and at 12 months (either 12 or 6
months of Val, p  0.0001). The major contribution in risk score reduction was due to an increase in small ar-
tery elasticity and a decrease in BP, and after 12 months there was a reduction in left ventricular mass index
(p  0.03).
Conclusions Valsartan can slow progression and/or reverse early cardiovascular disease in asymptomatic high-risk patients
with prehypertension or BP controlled to 140/90 mm Hg. (J Am Coll Cardiol 2007;50:835–9) © 2007 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.03.065f
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oost cardiovascular (CV) events are a consequence of a
rogressive atherosclerotic process that can be detected long
efore symptoms develop (1). Dysfunction of the vascular
ndothelium seems to be a key in the progression to
therosclerosis and CV events (2). Identifying individuals
ith early markers for this vascular disease process raises the
ossibility for pharmacotherapy to slow the progression and
elay or prevent future morbid events (3,4).
Most attempts to identify individuals at risk for CV
vents have involved screening for risk factors that are
tatistically associated with future CV events (5). This
pproach does not provide any insight as to how the risk
rom the Rasmussen Center for Cardiovascular Disease Prevention, Cardiovascular
ivision, University of Minnesota Medical School, Minneapolis, Minnesota. This
ork was supported by a research grant from Novartis Pharmaceuticals. Drs. Duprez
nd Cohn are consultants for, members of the Speakers’ Bureau for, and have received
esearch grants from Novartis Pharmaceuticals. Dr. Cohn has equities in Hyperten-
ion Diagnostics Inc.(
Manuscript received December 18, 2006; revised manuscript received February 28,
007, accepted March 6, 2007.actors are impacting the biologic target organs, the vascu-
ature, and the heart. Indeed, these traditional risk factors
o not seem to be useful in stratifying the severity of disease
n individual patients (6).
See page 840
The role of angiotensin II, the key mediator of the
enin-angiotensin-aldosterone system (RAAS), in the
athophysiology of CV disease is well known (7). Large-
cale, well-controlled clinical trials in high-risk popula-
ions have demonstrated that angiotensin II receptor
lockers (ARBs) reduce CV morbidity and mortality (8).
s the underlying mechanisms of vascular disease and the
ffects of ARBs on these processes have been further
efined, the therapeutic focus has begun to shift toward
revention of disease progression at earlier stages. Non-
nvasive diagnostic tests are now available to assess
therwise healthy individuals for subclinical CV disease
9). Our aim in this pilot trial was to examine whether the
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The DETECTIV Pilot Study August 28, 2007:835–9CV benefit of the ARB val-
sartan (Val) extends to asymp-
tomatic individuals with evi-
dence of early CV disease in a
randomized, double-blind,
placebo-controlled study.
Methods
Subjects. Patients screened in
the Rasmussen Center for CV
Disease Prevention at the Uni-
versity of Minnesota were eval-
uated for participation in the
DETECTIV (DEtection and
Treatment of Early Cardiovas-
cular disease Trial: Intervention
with Valsartan) pilot study. Pa-
tients’ characteristics are de-
scribed in the Results section.
The study was approved by the
local institutional review board.
easurements and study parameters. The Rasmussen
enter screening consists of assessment of vascular and
ardiac function and structure on the basis of 8 nonin-
asive tests performed in 1 h by a single technologist and
blood and urine test analyzed in the laboratory (9).
hese tests include the following:
MALL AND LARGE ARTERY ELASTICITY. Radial artery pulse
aves are registered with the CV Profilor (Hypertension
iagnostics, Eagan, Minnesota). Small artery (C2) and
arge artery (C1) elasticity are derived from the pulse
ontour analysis.
ITTING REST AND UPRIGHT EXERCISE BLOOD PRESSURE.
itting blood pressure (BP) is measured by standard sphyg-
omanometry at rest. The patient then stands on a tread-
ill, and BP is measured before and at the end of a 3-min
orkload at 5 METS on the basis of a treadmill speed of 2.3
ph at a slope of 7%.
Abbreviations
and Acronyms
ARB  angiotensin II
receptor blocker
A/V  arteriole-to-venule
BP  blood pressure
C1  large artery elasticity
C2  small artery elasticity
CV  cardiovascular
DBP  diastolic blood
pressure
LVMI  left ventricular
mass index
Plac  placebo
RDS  Rasmussen Disease
Score
SBP  systolic blood
pressure
Val  valsartan
ange of Values of Markers for RDS
Table 1 Range of Values of Markers for RDS
Test Normal
RDS 0
Large artery elasticity (C1)
Small artery elasticity (C2)
Resting BP (mm Hg) SBP 130 and DBP 85
Exercise BP (mm Hg) SBP rise 30 and SBP 169
Retinal vasculature A/V ratio 3:5
Carotid IMT
Microalbuminuria (mg/mmol) 0.6
Electrocardiogram No abnormalities
LV ultrasound LVMI (g/m2) 120
BNP (pg/dl) 50/V ratio  arteriole-to-venule ratio; BNP  B-type natriuretic peptide; BP  blood pressure; DBP  dias
ass index; RDS  Rasmussen Disease Score; SBP  systolic blood pressure.PTIC FUNDUS DIGITAL PHOTOGRAPHY. Optic fundus
hotos are taken with a digital camera (Canon, Greenville,
outh Carolina). Fundus photos are analyzed for the
rteriole-to-venule (A/V) ratio and the presence of A/V
rossing changes.
AROTID INTIMAL-MEDIA THICKNESS. Ultrasound with a
onosite Titan (Sonosite, Inc., Bothell, Washington) is
mployed to measure intimal-media thickness 1 cm distal
o the carotid bulb and to identify localized carotid
laques.
ICRO-ALBUMINURIA. A spot urine sample is analyzed for
lbumine/creatinine ratio.
LECTROCARDIOGRAPHY. A standard 12-lead electrocar-
iogram is evaluated for evidence of hypertrophy, repolar-
zation abnormalities, or conduction abnormalities.
EFT VENTRICULAR MASS INDEX. Left ventricular (LV)
ltrasound is performed with the Sonosite Titan, and left
entricular mass index (LVMI) was calculated according the
ormula of Devereux.
LASMA B-TYPE NATRIURETIC PEPTIDE. A venous blood
ample is analyzed for plasma B-type natriuretic peptide
BNP) with a Biosite Triage Platform (Biosite Inc., San
iego, California).
Each test is scored as 0 if normal, 1 for borderline, and 2
or abnormal. The criteria for normal and abnormal has
een established on the basis of large published databases, as
eported previously (9). The 10 tests therefore provide a
otal score from 0 to 20, which is called the Rasmussen
isease Score (RDS). Table 1 summarizes the range of
alues of markers for the RDS. We have arbitrarily estab-
ished, on the basis of experience in a large screened
opulation, a score of 6 or more as indicative of definite CV
bnormalities (9).
Entrance criteria for DETECTIV included an RDS of
6, BP below 140/90 mm Hg without or with antihyper-
ensive therapy, and cholesterol levels controlled with or
ithout statin therapy according to current guidelines.
Borderline Abnormal
1 2
(age- and gender-dependent)
(age- and gender-dependent)
SBP 130–139 or DBP 85–89 SBP 140 or DBP 90
SBP rise 30–39 or SBP 170–179 SBP rise 40 or SBP 180
atio 3:5 or mild A/V crossing changes A/V ratio 1.2 or A/V nicking
(age- and gender-dependent)
0.61–0.99 1.00
Nonspecific abnormality Diagnostic abnormality
120–129 130
51–99 100A/V rtolic blood pressure; IMT  intima-media thickness; LV  left ventricular; LVMI  left ventricular
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August 28, 2007:835–9 The DETECTIV Pilot Studyxclusions included prescription for an ARB, another
erious medical illness likely to limit survival, or unlikeliness
o be compliant with the regimen.
After the initial screen, patients were randomly assigned
ouble-blind to receive Val 160 mg once daily or matching
lacebo (Plac) for 6 months. At 6 months the full screening
esting was repeated. Then all the study patients (Val and
lac group) were given Val 160 mg once/day for the next 6
onths. At 12 months all the studies were repeated.
At baseline a fasting venous blood sample was taken for
he determination of total cholesterol, triglycerides, low-
ensity lipoprotein (LDL) and high-density lipoprotein
HDL) cholesterol, and glucose.
tatistical analysis. Descriptive values are expressed as
ean  SD for variables with normal distribution or
edians and inter-quartile ranges for variables with non-
ormal distribution. Unpaired t test was used to compare
he group means for variables with normal distribution.
ann-Whitney U test was used to compare medians and
aseline Demographics and Clinicalharacteristics of t e Study Popul tion (n  76)
Table 2 Baseline Demographics and ClinicalCharacteristics of the Study Population (n  76)
Placebo (n  38) Valsartan (n  38)
Age (yrs) 54 11 57 9
Male/female 22/16 24/14
Height (m) 1.72 11 1.71 11
Weight (kg) 82.0 15.8 85.8 18.7
BMI (kg/m2) 27.8 4.9 28.1 5.3
Cholesterol (mg/dl) 194.1 29.6 198.1 34.4
LDL cholesterol (mg/dl) 117.0 25.3 125.1 26.1
HDL cholesterol (mg/dl) 52.3 13.6 46.2 15.3
Triglycerides (mg/dl) 126.3 64.3 154.4 119.4
Glucose (mg/dl) 89.5 9.0 87.1 9.0
here are no significant differences for all parameters at baseline between the placebo and
alsartan groups.
BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density lipoprotein.
DS and its Individual Components at Baseline, 6 Months,nd 12 Months in the Plac (Last 6 Months Was Single-Blind Val) a
Table 3 RDS and its Individual Components at Baseline, 6 Monand 12 Months in the Plac (Last 6 Months Was Single
Plac
Parameter Baseline Plac 6 Months Plac 12
RDS 9.0 2.1 6.8 2.6*
SBP (mm Hg) 134.4 11.4 126.5 10.9*
DBP (mm Hg) 82.0 8.7 78.7 8.1†
C1 (ml/mm Hg  10) 13.9 4.0 15.2 6.6
C2 (ml/mm Hg  100) 5.05 2.88 5.60 3.20†
Exercise SBP rise (mm Hg) 30.7 18.4 22.8 12.1‡
Exercise DBP fall (mm Hg) 7.7 14.3 7.2 11.0
Carotid IMT (mm) 0.840 0.329 0.815 0.276
Retinal score 1.2 0.8 1.2 0.8
Micro-albuminuria (mg/mmol) 0.78 (0.91) 0.76 (0.59)
LVMI (mg/m2) 93.0 21.0 87.6 21.5
BNP 20.0 (27.3) 13.2 (35.2)
ECG score 0.7 0.8 0.5 0.7
ata are presented as mean SD, except for microalbuminuria and plasma B-type natriuretic pe
p  0.001; §p  0.01.
C1  large artery elasticity; C2  small artery elasticity; DBP  diastolic blood pressure; ECG  enterquartile ranges for variables with non-normal distribu-
ion. A paired Student t test was used to compare the
hanges from baseline to 6 and 12 months within 1 group.
hi-square test was used to compare nominal variables. For
ll tests a p value  0.05 was considered as statistically
ignificant. Statistical analysis was performed with a stan-
ard statistical program package (STATVIEW, version 5.0,
BACUS CONCEPT Inc., Berkley, California).
esults
ighty subjects were initially randomized into DETEC-
IV; 6 withdrew early in the study, 2 because of an
nrelated medical complication, and 4 because of with-
rawn consent. The 76 subjects followed to completion are
escribed in Table 2.
Table 3 summarizes the RDS of the 10 tests at baseline
nd after 6 months in Plac and Val groups and after 12
onths when both groups were treated with Val. During
he first 6 months of double-blind randomization to Val
ersus Plac, the RDS fell in both groups, but the fall was
ignificantly (p  0.03) greater in the Val group. The
hange in RDS from 6 to 12 months in the Plac group was
ighly significant (p  0.0001). Patients assigned to Val at
aseline exhibited modest further improvement from 6 to
2 months with continuation of Val (p  0.01). After 12
onths the decline in RDS in Val averaged 3.8 units, or a
4% reduction in the CV abnormalities identified. A similar
eduction was noted in the initial Plac group treated the last
months with Val.
Because the RDS represents a scoring system based on
hreshold levels of individual components of the disease
core, the individual measurement changes were compared.
mall artery elasticity (C2) increased at 6 months by 57% in
esponse to Val (p  0.0001) but by only 9% in response to
lac (p  0.38), and the difference was highly significant
l Groups
Val) and Val Groups
Val
hs Plac/Val Baseline Val 6 Months Val 12 Months Val/Val
 2.7* 8.6 2.4 5.5 2.5* 5.0 2.5*
 15.5* 136.9 12.5 120.9 11.9* 118.8 15.5*
 10.3† 83.6 9.9 73.1 7.7* 74.1 9.3*
 5.3 14.3 4.4 15.4 4.5 17.0 5.6
 3.06§ 4.19 2.37 6.58 3.57* 7.43 4.18*
 11.0§ 31.6 15.1 26.1 14.8† 23.3 15.9‡
 5.4 11.7 7.1 7.8 5.0† 7.9 6.0†
 0.406 0.811 0.238 0.780 0.253 0.786 0.267
 0.8 1.3 0.7 1.3 0.7 1.2 0.8
(0.54) 0.50 (0.54) 0.51 (0.56) 0.52 (0.41)
 17.1 87.9 17.1 86.6 22.4 82.3 19.2†
(31.7) 17.7 (30.9) 13.2 (21.3) 19.1 (31.3)
 0.6 0.4 0.7 0.4 0.7 0.3 0.6
BNP) for which data are presented as median and interquartiles (IQs). *p  0.0001; †p  0.05;nd Va
ths,
-Blind
Mont
5.1
120.7
75.3
16.9
6.56
19.4
5.7
0.829
1.2
0.63
85.0
16.8
0.4
ptide (lectrocardiogram; Plac  placebo; Val  valsartan, other abbreviations as in Table 1.
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The DETECTIV Pilot Study August 28, 2007:835–9p  0.01). Systolic blood pressure (SBP) and diastolic
lood pressure (DBP) decreased more in the Val arm
ompared with in the Plac arm (p  0.01).
After 12 months’ therapy the Plac patients who had
eceived Val for 6 months exhibited a significant 30%
ncrease from baseline in small artery elasticity (p  0.001),
ut this was significantly smaller (p  0.02) than the 77%
ncrease in the group that had received Val for 12 months.
his improvement in elasticity was characterized by a
rogressive alteration in the arterial pulse wave with reduc-
ion in the late systolic reflected wave.
Structural markers of CV disease were not altered at 6
onths, but by 12 months the group who had received Val
or the entire trial exhibited a significant decrease in LVMI
p  0.05). The other measures of vascular and cardiac
unction and structure were not significantly altered by Val.
iscussion
he pilot DETECTIV study allowed evaluation of the
fficacy of Val versus Plac on the RDS and the 10 contin-
ous variable components of the score in high-risk asymp-
omatic individuals with either prehypertension or con-
rolled BP 140/90 mm Hg. During 6 months of Val,
ascular function benefits, including improved small artery
lasticity and a reduction in SBP and DBP within the
ormotensive range, were identified. These changes ac-
ounted for a significantly greater reduction in RDS at
months, further supported by a similar benefit from 6
onths to 1 year in the group randomized to Val at 6
onths.
The RDS is heavily dependent on structural abnormalities,
nd it is unlikely that 6 months would be a long enough time
o detect gross benefits on structure. Nonetheless, treatment
ith Val for 12 months exerted a favorable effect on LVMI.
urthermore, from 6 to 12 months there was a further
ncrease in small artery elasticity in the group randomized
or 12 months to Val, and the improvement in elasticity was
ignificantly greater after 12 months than after 6 months of
herapy. This delayed increase in small artery elasticity is
onsistent with a slowly developing structural effect super-
mposed on the early functional benefit. These data on
elayed cardiac and vascular effects suggest that longer-term
herapy might display more dramatic benefits on structure
f the vasculature and heart.
Angiotensin II has been implicated as a major contributor
o endothelial dysfunction, hypertrophy of the vascular wall,
rterial remodeling and inflammation, and consequently to
educed arterial compliance (8,10). Remodeling of small
esistance arteries might be one of the earliest manifesta-
ions of target-organ damage and can be demonstrated
efore clinically apparent CV disease develops (11). Reduc-
ng BP might not suffice to improve outcomes in hyperten-
ion unless vascular remodeling is also corrected and endo-
helial function is improved. There is now growing evidence
hat ARB can favorably affect resistance artery structure andndothelial function. In recent studies in hypertensive pa-
ients, Val therapy has been demonstrated to improve
ompliance of the small and large arteries (12) and to
mprove endothelial function (13). Modest improvement of
DS in the Plac group during the first 6 months was related
rimarily to a decrease in BP and a modest increase in small
rtery elasticity. These effects might reflect the counseling
egarding lifestyle changes and its positive influence on BP
owering and small artery elasticity. However this effect was
ess pronounced than compared with the first 6 months of
al.
The vascular and cardiac tests included in DETECTIV are
ll viewed as markers for disease progression that are predictive
f CV risk. The disease identified by these markers progresses
ver many years, so it is not surprising that 6 to 12 months of
herapy with an ARB was effective in improving only a few of
he baseline abnormalities. A longer study in a larger popula-
ion would likely provide more robust evidence for improve-
ent in vascular and cardiac health.
As a pilot study DETECTIV was not designed to assess
orbid events. Indeed, the population eligible for partici-
ation in DETECTIV had no evidence for overt disease
hat would place them at high immediate risk (14). The goal
n this population is to slow disease progression from its
arliest detection to hopefully delay or prevent morbid
vents during the patients’ productive years. Demonstration
f this morbid event prevention would require a long study
n a very large population. In the meantime, however,
urrogate markers for the biological process in the arteries
nd heart that progress to morbid events should serve as an
ttractive means of identifying those at risk and demonstrat-
ng their response to therapy. Indeed, asymptomatic indi-
iduals with prehypertension or with BP controlled
140/90 mm Hg with high RDS might be candidates for
harmacotherapy, whereas those with low scores could be
iven life-style recommendations. The sensitivity and spec-
ficity of these scores would need to be documented in
rospective studies.
eprint requests and correspondence: Dr. Daniel A. Duprez,
ardiovascular Division, VCRC-Room 270, Mayo Mail Code
08, University of Minnesota Medical School, 420 Delaware
treet Southeast, Minneapolis, Minnesota 55455. E-mail:
upre007@umn.edu.
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